|
|
Article: Eisai Inc. Assumes U.S. Distribution Responsibilities for Aciphex(R); Company Accomplishes Long-Term Goal for Aricept(R) and Aciphex(R).
- Article from:
- PR Newswire
- Article date:
- January 7, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TEANECK, N.J., Jan. 7 /PRNewswire/ -- Eisai Inc. announced today that the company has assumed the U.S. distribution responsibilities for Aciphex(R) (rabeprazole sodium) from Janssen Pharmaceutica, Inc. affiliate JOM Pharmaceutical Services. Eisai and Janssen will continue to co-promote Aciphex(R), a proton pump inhibitor (PPI) prescribed for gastroesophageal reflux disease (GERD), in the United States. The partnership with Janssen for sales, marketing and further clinical development remains unchanged for the duration of the co-promotion agreement.
Effective December 29, 2003, Eisai is fulfilling purchase orders for Aciphex(R) from a contract distribution ...